<DOC>
	<DOCNO>NCT00839228</DOCNO>
	<brief_summary>Up half patient clinical feature heart failure find normal heart pump function . Recently investigator show drug call perhexiline markedly improve exercise capacity symptoms patient heart failure associate impaired cardiac pump function . In proposal investigator ass whether perhexiline beneficial effect patient heart failure normal heart pump function .</brief_summary>
	<brief_title>Perhexiline Therapy Heart Failure With Preserved Ejection Fraction Syndrome</brief_title>
	<detailed_description>Up 50 % patient symptoms heart failure preserve leave ventricular ejection fraction ( HFpEF syndrome ) . Current therapy systolic heart failure target inducing vasodilation counteract neuro-endocrine activation . There lack correspond evidence base treatment HEpEF . We previously show perhexiline , agent increase efficiency energy production shift substrate utilization free fatty acid towards glucose , highly effective improve exercise capacity , symptom cardiac function patient systolic heart failure . We also recently show energy deficiency play major role pathophysiology HFpEF . In proposal therefore aim investigate effectiveness perhexiline 70 HFpEF patient , 3 month randomise , double-blind , control trial . An interim analysis plan 20 patient .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Perhexiline</mesh_term>
	<criteria>HFpEF define : Clinical feature consistent heart failure LVEF â‰¥ 50 % , evidence significant valvular disease No hypertrophic cardiomyopathy , evidence pericardial constriction Peak VO2 &lt; 80 % predict , RER &gt; 1 pattern gas exchange metabolic exercise test indicate cardiac cause limitation ) Patients recruit sinus rhythm BMI &gt; 35 Objective evidence lung disease formal lung function test Reversible myocardial ischaemia contrastenhanced myocardial stress Echocardiography , evidence exerciseinduced mitral regurgitation ( &gt; 2+ ) Impaired hepatic function ; know hypersensitivity perhexiline</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>diastolic dysfunction</keyword>
	<keyword>cardiac energetics</keyword>
	<keyword>perhexiline</keyword>
	<keyword>magnetic resonance spectroscopy</keyword>
</DOC>